Skip to main content
China Resources Pharmaceutical Group Limited logo

China Resources Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 3320 ISIN · HK0000311099 LEI · 3003004H1KDKMJ8JD874 HKEX Manufacturing
Open in API
Filings indexed 813 across all filing types
Latest filing 2025-12-15 Capital/Financing Update
Country HK Hong Kong
Listing HKEX 3320

About China Resources Pharmaceutical Group Limited

http://www.crpharm.com

China Resources Pharmaceutical Group Limited operates an integrated pharmaceutical value chain encompassing research and development, manufacturing, distribution, and retail of medicines and healthcare products. As an investment holding company, it manages a diverse portfolio focused primarily on the domestic market. Its manufacturing capabilities span multiple therapeutic areas, including chemical drugs, biological drugs, natural medicine, and traditional Chinese medicine. The group leverages its extensive distribution network and retail operations to ensure broad market coverage across China.

Recent filings

Filing Released Lang Actions
INSIDE INFORMATION COMPLETION OF THE ISSUE OF THE FIRST TRANCHE OF THE MEDIUM TERM NOTES 2025 IN THE PRC
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding the completion of the issuance of medium-term notes by a subsidiary of China Resources Pharmaceutical Group Limited. It details the principal amount, term, coupon rate, and the intended use of proceeds. This falls under the category of company fundraising and financing activities, which corresponds to the 'CAP' (Capital/Financing Update) filing type.
2025-12-15 English
CHANGE OF COMPANY SECRETARY AND AUTHORISED REPRESENTATIVE
Board/Management Information Classification · 100% confidence The document is an official announcement regarding the resignation of a company secretary and the appointment of a new one. This falls under the category of changes in senior management or key corporate officers, which is classified as MANG (Board/Management Information).
2025-12-15 English
CONTINUING CONNECTED TRANSACTIONS FRAMEWORK LOAN AGREEMENTS 2025
Regulatory Filings Classification · 95% confidence The document is an official announcement from China Resources Pharmaceutical Group Limited regarding 'Continuing Connected Transactions' specifically related to 'Framework Loan Agreements 2025'. It details the terms, parties, interest rates, and annual caps for these financial arrangements. Under the Hong Kong Stock Exchange Listing Rules, such transactions between a listed company and its connected persons (like parent companies CRI and CR Holdings) require a formal announcement. This document is a regulatory disclosure of a financial arrangement rather than a report publication announcement, a financial report, or a general regulatory filing, making it a specific type of corporate transaction disclosure.
2025-12-15 English
CONTINUING CONNECTED TRANSACTIONS THE AMENDED BUSINESS TRAVEL SERVICES FRAMEWORK AGREEMENT 2026
Regulatory Filings Classification · 98% confidence The document is an official announcement from China Resources Pharmaceutical Group Limited regarding 'Continuing Connected Transactions' under the Hong Kong Stock Exchange Listing Rules. It details a framework agreement for business travel services, including pricing policies, historical transaction amounts, and proposed annual caps. As it is a formal regulatory disclosure regarding corporate transactions that does not fit into specific categories like M&A (TAR) or Share Issues (SHA), it is classified as a general Regulatory Filing (RNS).
2025-12-10 English
INSIDE INFORMATION REGISTRATION OF MEDIUM TERM NOTES BY THE NATIONAL ASSOCIATION OF FINANCIAL MARKET INSTITUTIONAL INVESTORS
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the registration of medium-term notes by a subsidiary of China Resources Pharmaceutical Group Limited. It details the regulatory approval (Notice of acceptance of registration) for a future debt issuance (RMB 3 billion). This falls under the category of company fundraising and financing activities. Since it is an announcement of a financing plan rather than a report publication or a specific share transaction, 'CAP' (Capital/Financing Update) is the most accurate classification.
2025-12-01 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2025
Share Issue/Capital Change Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in their securities, including issued shares, treasury shares, and share options. Since it details changes in share capital and securities, it falls under the category of share issues and capital changes.
2025-12-01 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.